ReviewLeukemia2006
Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death.
Review in Leukemia, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00961064 (A Pilot Study of a Thrombopoietin-Receptor Agonist), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Who cites it
20 citing papers in PubMed, 64 citations in OpenAlex.
- An interpretable machine learning model for biomarker identification and diagnostic nomogram development in hypo-productive thrombocytopenia.Scientific reports · 2026Article
- Observational
- An unconquered challenge in MDS: review of pathophysiology, clinical manifestations, and management options of MDS with thrombocytopenia.Annals of hematology · 2025Review
- Autophagy and its consequences for platelet biology.Thrombosis research · 2023Review
- Lack of COL6/collagen VI causes megakaryocyte dysfunction by impairing autophagy and inducing apoptosis.Autophagy · 2023Article
- Anti-glycoprotein antibodies and sequestration pattern of indium-labeled platelets in immune thrombocytopenia.Blood advances · 2022Article
- Utilizing network pharmacology to explore potential mechanisms of YiSui NongJian formula in treating myelodysplastic syndrome.Bioengineered · 2021Article
- Comparative study of IgG binding to megakaryocytes in immune and myelodysplastic thrombocytopenic patients.Annals of hematology · 2021Article
- Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis.Frontiers in oncology · 2020Article
- Dysregulated megakaryocyte distribution associated with nestinBlood advances · 2019Article
- Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia.Scientific reports · 2019Article
- Non-apoptotic functions of caspases in myeloid cell differentiation.Cell death and differentiation · 2017Review
- Identifying and enriching platelet-producing human stem cell-derived megakaryocytes using factor V uptake.Blood · 2017Article
- Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP).Journal of clinical medicine · 2017Review
- Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.Leukemia · 2016Review
- Role of autophagy in megakaryocyte differentiation and platelet formation.International journal of physiology, pathophysiology and pharmacology · 2016Review
- Suppression of in vitro megakaryopoiesis by maternal sera containing anti-HPA-1a antibodies.Blood · 2015Article
- Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes.Haematologica · 2012Article
- Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.Seminars in thrombosis and hemostasis · 2011Review
- Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.Drug design, development and therapy · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet production requires compartmentalized caspase activation within megakaryocytes. This eventually results in platelet release in conjunction with apoptosis of the remaining megakaryocyte. Recent studies have indicated that in low-risk myelodysplastic syndromes (MDS) and idiopathic thrombocytopenic purpura (ITP), premature cell death of megakaryocytes may contribute to thrombocytopenia. Different cell death patterns have been identified in megakaryocytes in these disorders. Growing evidence suggests that, besides apoptosis, necrosis and autophagic cell death, may also be programmed. Therefore, programmed cell death (PCD) can be classified in apoptosis, a caspase-dependent process, apoptosis-like, autophagic and necrosis-like PCD, which are predominantly caspase-independent processes. In MDS, megakaryocytes show features of necrosis-like PCD, whereas ITP megakaryocytes demonstrate predominantly characteristics of apoptosis-like PCD (para-apoptosis). Triggers for these death pathways are largely unknown. In MDS, the interaction of Fas/Fas-ligand might be of importance, whereas in ITP antiplatelet autoantibodies recognizing common antigens on megakaryocytes and platelets might be involved. These findings illustrate that cellular death pathways in megakaryocytes are recruited in both physiological and pathological settings, and that different forms of cell death can occur in the same cell depending on the stimulus and the cellular context. Elucidation of the underlying mechanisms might lead to novel therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.